Protagonist Therapeutics, Inc. (PTGX)
$136.28-1.60%Close
SELLRECOVERY · day 4
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $8.8B
- Beta
- 1.79
- P/E (TTM)
- 111.88
- Short % float
- 17.80%
- Days to cover
- 11.5
- SI change
- +14.8%
- 1W
- -3.29%
- 1M
- -4.97%
- vs SPY 1W
- -2.31%
- vs SPY 1M
- -6.83%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS & VALIDATION
[SCORES & PROFILE]
- FUND
- 23
- VALUE
- 7
- GROWTH
- 49
- GARP
- 12
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC7.2%
REV YoY-
ROE12.0%
EPS YoY-
ROA9.4%
GROSS100
OP21
NET29
[VALUATION]
P/E TTM111.88
P/E FWD-
SECTOR PE20.48
INDUSTRY PE13.99
P/B10.68
P/FCF-
EV/EBITDA97.90
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E1.10
ALTMAN Z-
CURR RATIO21.71
ND/EBITDA-
BETA1.79
[BEST COMBO]VALIDATED · V5
ENTER · HOLD · EXIT · WAITOne next-open action from five signal families, published only when the held-out edge survives 20 bps costs.
Today's action with its out-of-fold profit factor, trade count and family votes.
[WHITE ARROW]FULL HISTORY
SELL
Directional consensus stays BUY or SELL until the model reverses; trades fill next session open.
PROFIT FACTOR2.1
TRADES42
[REGIME]FULL HISTORY
RECOVERY
BULL or RECOVERY stays invested; BEAR or CRISIS exits at the next session open.
Profit factor and trade count for holding this symbol only in BULL or RECOVERY.
[EXHAUSTION]NOW
Whether buyers or sellers are stretched today, the latest release and its strength.
Company news
FAQ
- What is LOPJLB’s current signal on PTGX?
- LOPJLB’s latest quantitative signal on Protagonist Therapeutics, Inc. (PTGX) is SELL in a RECOVERY regime. Signals are updated daily.
- What market regime is PTGX in?
- Protagonist Therapeutics, Inc. (PTGX) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does Protagonist Therapeutics, Inc. (PTGX) do?
- Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials f…